May 4, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Grünenthal, a pharmaceutical company headquartered in Aachen in Germany, on a series of clinical single-cell based proteomics projects.
Collaboration with Frame Cancer Therapeutics
April 26, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Frame Cancer Therapeutics, an Amsterdam pharmaceutical company, on a series of clinical proteomics projects.
Collaboration with Ludwig Cancer Research.
April 21, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Ludwig Cancer Research Center on a series of clinical proteomics projects.
Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media
Complete Omics’ Clinical Proteomics team is proud to share with you the recent media coverage of our efforts in paving the way for the ultimate personalized cancer therapeutics. Our efforts toward achieving this ultimate goal of cancer treatment were reported by GenomeWeb, The Scientist, Precision Oncology News, News Wise, Fierce Biotech, etc. One of our clinical proteomics pipelines can help identify personalized cancer neoantigens that can be further targeted by a variety of therapeutic approaches, such as mRNA cancer vaccine, therapeutic peptide injection, engineering cell therapy, and here two bispecific antibody approaches.
Complete Omics published novel technologies on SCIENCE and SCIENCE IMMUNOLOGY.
Complete Omics Inc. (official website) – For years, personalized cancer therapeutics has been an ultimate goal for all cancer patients and doctors. Healthcare providers and scientists working across the biopharmaceutical industry have been tirelessly committed to bringing to patients more and more, better and better, personalized cancer therapeutic approaches.
Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer diagnostics and treatment through our multi-omics platform that we have published on Science Immunology and Science.
Collaboration with Drs. Bai and Staedtke in JHH
Feb 10, 2021 | BALTIMORE – Complete Omics’ Clinical Metabolomics team announced a collaboration with Dr. Renyuan Bai and Dr. in Johns Hopkins Medicine on a series of metabolomics targeted detection projects.
Congratulations to our lab alumni founders in Thrive Earlier Detection.
NEW YORK – Exact Sciences has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection, a molecular diagnostics company founded by Vogelstein lab trainees from Johns Hopkins, for cash and stock consideration of up to $2.15 billion.
Collaboration with MD Anderson
Aug 19, 2020 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with MD Anderson on a variety of molecular diagnostics projects.
Collaboration with MSKCC
Mar 29, 2020 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with, MSKCC, a world leader in cancer care on a variety of molecular diagnostics projects.
MANA-SRM pipeline and its application in personalized cancer therapeutics.
NEW YORK – Researchers at Johns Hopkins University have developed a targeted mass spec method for measuring cancer-linked neoantigens.
Described in a study published last month in Cancer Immunology Research, the method could prove useful both for studying tumor immunology and in the development of personalized cancer immunotherapies, said Qing Wang, first author on the paper and founder and CEO of clinical omics firm Complete Omics.
